|Over a week ago|
Oragenics says says study shows CoV-2 S-2P generated neutralizing antibodies » 07:4407/2207/22/20
Oragenics said in a…
Oragenics said in a release, "the National Institutes of Health, or NIH, created stabilized pre-fusion spike protein (CoV-2 S-2P) licensed by the Company has generated neutralizing antibodies in mice during immunization against SARS-CoV-2, the virus that causes COVID-19. The NIH's preclinical study shows that this spike protein, adjuvanted with the TLR-4-agonist Sigma Adjuvant System (a TLR-4 agonists that induces T cell activation), generates neutralizing antibody titers in both a pseudovirus neutralization assay and a plaque reduction neutralization titer assay. In addition, this immunization produced a balanced Th1/Th2 response."
|Over a month ago|
Oragenics files to sell 18.4M shares of common stock for holders 16:1205/2905/29/20
Oragenics, Aragen Bioscience enter agreement to advance TerraCoV2 » 08:2705/1905/19/20
Oragenics announced, that…
Oragenics announced, that through its wholly-owned subsidiary, Noachis Terra, it has entered into an agreement with Aragen Bioscience, a contract research organization focused on accelerating pre-clinical biologics product development, to advance TerraCov2 the Company's SARS CoV-2 vaccine candidate. Under the terms of the agreement, Aragen will provide cell line development services to Oragenics to aid in the development of Oragenics' TerraCoV2, which could provide specific immunity from the novel coronavirus ("SARS-CoV-2"), the root cause of coronavirus disease 2019 ("COVID-19").
|Over a quarter ago|
Oragenics acquires Noachis Terra for $1.925M in cash » 06:0305/0405/04/20
Oragenics announced its…
Oragenics announced its acquisition of Noachis Terra, following its entry into a stock purchase agreement, to develop and commercialize TerraCoV2, a vaccine candidate which could provide specific immunity from the novel coronavirus, the root cause of coronavirus disease 2019. Noachis Terra holds a worldwide, nonexclusive license to the TerraCoV2 vaccine candidate from the National Institute of Allergy and Infectious Diseases. The company's acquisition of Noachis Terra and its TerraCoV2 immunization product candidate represents its first step towards accessing pioneering technologies to reduce the global threat posed by COVID-19, which aligns with the company's existing anti-infective programs. As a result of the acquisition, the company (i) paid an aggregate of $1.925M in cash, a portion of which was applied to retire outstanding obligations of Noachis Terra with the balance being paid to Hernandez, (ii) issued 9.2M shares of common stock of the Company and warrants to purchase 9,200,000 shares of common stock of the company, carrying an exercise price of $1.25 per share and a five-year term, and (iii) may be obligated to pay Hernandez certain contingent cash consideration in the future in accordance with the Stock Purchase Agreement, in exchange for 100% of the issued and outstanding common stock of Noachis Terra, which became a wholly-owned subsidiary of the company. Pursuant to the Stock Purchase Agreement, the company is committed to filing a registration statement covering the newly-issued shares of common stock, while the exercise of the warrants to purchase shares of the company's common stock are subject to shareholder approval, which the company intends to solicit in connection with its 2020 annual meeting of the shareholders.
Oragenics downgraded to Neutral from Buy at H.C. Wainwright » 07:1004/1604/16/20
H.C. Wainwright analyst…
H.C. Wainwright analyst Yi Chen downgraded Oragenics to Neutral from Buy without a price target. Early top-line results from the company's Phase 2 trial of AG013 in oral mucositis failed to show statistical significance versus placebo, Chen tells investors in a research note. The analyst prefers to stay on the sidelines while awaiting additional data.
Oragenics reports early results from Phase 2 clinical trial of AG013 » 06:3204/1504/15/20
Oragenics announced that…
Oragenics announced that early top-line results of the company's Phase 2 clinical trial of AG013 in oral mucositis in chemoradiation in head and neck cancer patients did not demonstrate statistical significance on the primary endpoint of severe oral mucositis duration when compared to placebo. AG013 was found to be safe based on review of topline adverse event information.
Oragenics files $50M mixed securities shelf 16:1512/3112/31/19
Oragenics completes enrollment of Phase 2 clinical trial for AG013 in OM » 08:3412/0212/02/19
Oragenics announced the…
Oragenics announced the completion of enrollment in its ongoing double-blind, randomized, placebo-controlled Phase 2 trial of its lead product candidate, AG013, an easy to use oral rinsing system designed to prevent and treat oral mucositis, or OM. The ongoing Phase 2 trial is a double-blind, placebo-controlled, two-arm, multi-country, multi-center trial, in which 200 patients have been randomized in a 1:1 ratio to receive either AG013 or a placebo. The purpose of the study is to evaluate the safety, tolerability and efficacy of topically administered AG013 compared to placebo for reducing the incidence and severity of OM in patients undergoing traditional chemoradiation, or CRT, for the treatment of head and neck cancer, or HNC. Key measures include duration, time to development, and overall incidence of OM during the active treatment phase, which begins from the start of chemoradiation therapy and ends two weeks following its completion.
Oragenics announces bicyclic C/D ring study outcome published » 08:0911/1511/15/19
Oragenics announced the…
Oragenics announced the publication of the outcome of the a specific chemical synthesis of the bicyclic C/D ring of an analog of the company's lantibiotic compound, Mutacin 1140. The study was published in the recent issue of Journal of Peptide Science.
Oragenics says Phase 2 trial of AG013 reaches enrollment of 158 patients » 08:0509/2509/25/19
Oragenics announces it…
Oragenics announces it has enrolled 158 patients in its Phase 2 trial of AG013 for the treatment of severe oral mucositis. In addition, the Data and Safety Monitoring Board for the trial, recently met and reviewed safety data to date and has determined that the trial may continue with no adjustments or further review. The company is currently enrolling approximately 200 patients in 59 study sites in the United States and Europe.